Company News & Updates

Poster presentation highlighted promising pharmacology and behavioral results on lead candidate, TN-001, in preclinical studies. ‍ TN-001 is under development for both major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). TN-001 rapidly induces neuroplasticity, including synaptogenesis.‍

Accomplished physician-scientist brings more than 30 years of industry leadership experience and CNS drug development expertise.

Transneural has assembled a team of scientific and strategic experts in neuropsychiatry to take on the challenge of transforming outcomes for patients and families